<DOC>
	<DOCNO>NCT00093314</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy HuMax-CD20 treatment Chronic Lymphocytic Leukemia .</brief_summary>
	<brief_title>HuMax-CD20 Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Chronic Lymphocytic Leukemia Circulating lymphocytes specific level Circulating lymphocytes show certain marker Previous treatment rituximab alemtuzumab within 6 month prior enrollment study . Previous stem cell transplantation . Received follow treatment within 4 week prior enter trial : A ) Anticancer therapy , B ) Glucocorticoids unless less 10 mg per day , C ) Radiotherapy . HIV positivity . Hepatitis B hepatitis C. Other cancerous disease , except certain skin cancer cervix cancer . Certain serious medical condition , include kidney liver disease , psychiatric illness , stomach , heart , hormonal , nerve blood disease . Participation another trial different new drug 4 week prior enrollment study . Current participation clinical study . Pregnant breastfeed woman . Women childbearing age unable unwilling use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>B-cell Lymphoma</keyword>
</DOC>